ABSTRACT
Introduction
The tumor microenvironment is an important factor in the development and progression of cancer.
1,2 A subset of regulatory T-cells (Treg) in the tumor microenvironment, characterized by a CD4 + CD25
+ phenotype, has become the focus of interest, given the critical role of these cells in the modification of immune responses, particularly suppression of tumorassociated antigen-reactive lymphocytes. 1, 3 Identification of the forkhead transcription factor FOXP3 as a master regulator of Treg development enabled more precise definition of this cell population. 4, 5 It has been convincingly shown that FOXP3 is required for Treg suppressor activity, amplifying and fixing Treg molecular features, generating and maintaining their phenotype, 6 and that FOXP3 gene transfer to CD4 + cells is sufficient to induce transplantation tolerance. 7 Recent evidence suggests that the cellular composition of the tumor microenvironment, particularly the quantity of tumor-infiltrating Treg, can significantly modify the clinical outcome in hematologic malignancies, particularly in follicular lymphomas (FL) and classical Hodgkin's lymphomas (cHL).
8-11 Importantly, the transforming lymphomagenesis events in both FL and cHL probably occur during the socalled germinal center (GC) reaction, 12, 13 which is the most important step in B-cell maturation during T-cell dependent antigen responses.
14 The so-called follicular helper T cells (TFH) are thought to play a considerable role in inducing somatic hypermutation and immunoglobulin (Ig) class switching in B cells undergoing a GC reaction. [15] [16] [17] [18] It has been shown that Treg potently suppress TFH and TFH-mediated B-cell functions such as Ig production and B-cell survival. 19, 20 Moreover, FOXP3 + Treg can directly suppress and even kill B cells.
21, 22
The importance of tumor-infiltrating FOXP3 + cells in lymphomas has been addressed in only a few studies thus far. [9] [10] [11] [23] [24] [25] [26] [27] To further characterize the distribution and correlate the quantity of tumor-infiltrating FOXP3 + cells to phenotypic and clinical parameters in lymphomas, we performed a tissue microarray (TMA) analysis on previously validated TMA, encompassing 1019 cases, applying receiver operator characteristics (ROC)-based methods to determine prognostic cut-off levels of FOXP3 + cell density.
Design and Methods

Samples
Mature B-and T-cell lymphomas and cHL cases (n=1019) diagnosed between 1974 and 2001 and reclassified according to current criteria 28 were collected from the archives of the Institutes of Pathology at the Universities of Basel, Innsbruck and Bologna. Paraffin blocks were selected based on availability and preservation. Clinical and follow-up data (Table 1) were obtained from chart reviews. Tissue and clinical data were retrieved according to the regulations of the local institutional review boards and data protection laws. Details on treatment regimens and definitions of response, relapse and treatment failures are given in the online Supplementary Data. 
Tissue microarray construction
The tissue microarray (TMA) were constructed and validated as described elsewhere [29] [30] [31] [32] [33] [34] [35] (see Supplementary Data). In cases of FL, neoplastic GC were sampled for arraying. 
Morphometrical analysis
Statistics
Statistical analysis including data description was done using the Statistical Package of Social Sciences 14.0 software (Chicago, IL, USA). The agreement between immunohistochemical results from the TMA and conventional full-tissue sections was assessed using the κ statistics, a κ-value of ≥0.75 implying excellent agreement. The Pearson χ
2 statistic was used to analyze relationships between the markers and the clinical variables. Analysis of variables (ANOVA) was applied to assess mean differences between groups. The prognostic performance of these variables and determination of optimal cut-off values of continuous variables was established by ROC-curves plotting sensitivity versus 1-specificity. The optimal cut-off point was calculated using Youden's index (Y), where Y=sensitiv-ity+specificity-1, since this method can be applied when there is no particular requirement on sensitivity and/or specificity. 37 The results from the ROC analysis were considered in every disease entity for overall, disease-specific and failure-free survival. These survival rates were then analyzed by the Kaplan-Meier method applying the cut-off values calculated by the ROC/Y. Survival results for which the ROC or the Kaplan-Meier method indicated statistical significance (p<0.05) or borderline significance (p<0.1) were further considered. The impact of markers that seemed to be of significant or borderline prognostic significance in univariate analyses determined by multivariate analysis done using a Cox regression model. 
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Results
Patients and determination of phenotypic GC-like DLCBL
All the relevant clinical characteristics of the patients are shown in Table 1 . For additional life status data see Supplementary Data. Applying the modified Hans' algorithm (see Statistics), DLBCL cases were classified as phenotypically GC-like (n=81), non-GC DLBCL (n=98) or, due to lacking data on single markers from the decision tree, unclassifiable DLBCL (n=91).
FOXP3 expression and TMA validation
In normal tissues, FOXP3 was moderately expressed in tonsillar and nodal lymphocyte nuclei with a distribution accentuated in the subepithelial and marginal zones of the tonsils (mean 35±17 FOXP3 + cells/mm 2 marginal zone tissue), paracortical areas (mean 15±9 FOXP3 + cells/mm 2 paracortical tissue) and follicles of both tonsils and lymph nodes (mean 18±11 FOXP3 + cells/mm 2 GC tissue). Unequivocal co-expression of FOXP3 and CD4 or CD25, was detectable on double-stained slides, while expression of FOXP3 on CD4 or CD25-negative cells was not observed ( Figure 1A ).
Comparison of results of conventional lymphoma slides and TMA showed good concordance (κ=0.87), which was lower in FL (κ=0.79) and cHL (κ=0.80), and higher in SLL/CLL (κ=0.92), ALCL (κ=0.95) and DLBCL (κ=0.94).
Distribution of FOXP3
+ tumor-infiltrating lymphocytes FOXP3 + cells could be assessed on TMA for 677 (92%) Band T-cell lymphomas and 249 (89%) cHL ( ) and 0 to 22% (mean 1.8%) in cHL, being higher in FL, AILT, nodular sclerosis cHL, primary mediastinal B-cell lymphomas (PMBCL) and peripheral T-cell lymphomas (PTCL) and lower in marginal zone lymphomas (MZL), mantle cell lymphomas (MCL) and lymphocyte-rich cHL (Figure 1 B-F) . In cHL, FOXP3 + cells were rarely in the direct proximity to HRSC. We did not detect FOXP3-expression on the atypical cells of PTCL and AILT or on any B-cell lymphoma cells and HRSC (Figure1 B-F) . Despite in vitro data on the ability of the NPM/ALK oncoprotein to induce a Treg cell phenotype with expression of FOXP3 mRNA in ALCL, 38 we did not detect FOXP3 protein expression in the lymphoma nuclei of the four arrayed ALK + ALCL, although tumor-infiltrating FOXP3 + small lymphocytes were present. All morphometric results are summarized in Table 2 and partially shown in Figure 1B -F.
Statistics
Correlations of FOXP3 + cell quantity with infiltrating T cells and lymphoma transformation
There were specific associations between the numbers of 
Setting the cut-off values for FOXP3
+ cell quantity ROC showed significant discriminatory power considering overall, disease-specific and failure-free survival rates for the number of tumor-infiltrating FOXP3 + cells in FL, DLBCL, CLL/SLL and cHL (Table 3) . A typical ROC curve for the discriminatory power of the number of FOXP3 + cells is shown in Figure 2A . Comparison of the results linked to clinical end-points by the Kaplan-Meier method unequivocally showed the superior discriminating power of the cut-off levels calculated considering the ROC/Y compared to means, medians and quartile values (see Supplementary  Figure) .
Survival analysis associated with quantity of FOXP3 + cells
Overall, disease-specific and failure-free survival rates were analyzed by the Kaplan-Meier method applying cutoff values determined by the ROC/Y and primary dichotomized clinical characteristics. The absolute amount of tumor-infiltrating FOXP3 + cells was of significant prognostic importance for overall and disease-specific survival in DLBCL, disease-specific and failure-free survival in FL, and overall and failure-free survival in cHL ( Figure 2B-F) . A trend toward better overall survival was observed in AILT, with >40.4 FOXP3 + cells/mm 2 (p=0.191). All relevant results concerning the prognostic importance of tumor-infiltrating FOXP3 + cells are shown in Table 3 and Figure 2B -F. In a Cox regression model the amount of tumor-infiltrating FOXP3 + cells was of independent prognostic significance for failurefree survival in cHL and of borderline significance for overall survival in cHL and disease-specific survival in GC-like and non-GC DLBCL (Table 4) , in DLBCL, in general, not being independent of the International Prognostic Index (data not shown).
Discussion
Our analyses extended results of previous studies on tumor-infiltrating FOXP3 + cells in lymphomas by taking advantage of validated lymphoma TMA with continuous referencing to 1 mm 2 , application of commercially-available monoclonal antibodies in a large cohort (n=1019) of cases with distributions, except for SLL/CLL, similar to that expected in an average Middle European population, 39 and a ROC-curve based approach to calculate optimal cut-offpoints for the prognostic evaluation of FOXP3 + cell numbers. The soundness of our analysis, the multiple previous validations of the TMA used [29] [30] [31] [32] [33] [34] [35] as well as the κ-values for the comparison of results from conventional lymphoma slides and TMA guarantee the reliability of the data obtained. We clearly demonstrated that the FOXP3 + cell density varies between different lymphoma types and that do lymphoma-infiltrating FOXP3 + cells may represent important lymphoma/host microenvironment-modulators, since increased amounts of these cells can positively influence survival in FL, GC-like DLBCL and cHL. Because neither CD3 + nor CD4 + tumor infiltrating lymphocytes correlated with prognosis, but only the amount of FOXP3 + cells, the latter obviously do not simply reflect the T-cell infiltration (see last paragraph of the Discussion).
Our FOXP3 + data are concordant with flow cytometry data from 24 B-cell lymphoma patients 25 showing that CD4 + CD25
+ cells represent 17% of the median amount of 19% (i.e. 3%) CD4 + cells in the lymphoma specimens. Nevertheless, our results are partially at variance with those of other immunohistochemical studies.
9,10,26 Some differences between our results and those of these studies could be attributed to different anti-FOXP3 antibodies and dilutions (undiluted, clone 236A/E7M, 
© F e r r a t a S t o r t i F o u n d a t i o n 22510 [our study])
. Importantly, the antibody clone 236A/E7M stained a notably larger population of cells than another anti-FOXP3 monoclonal antibody (14-5779, eBioscience, San Diego, CA, USA), 40 and validation experiments of the staining specificity of mAbcam 22510 used at 1:25 dilution were not reported. 26 In FL, in particular, differences could be related to our a priori arraying of cores from neoplastic GC for TMA construction and consideration of conventional slides by Carreras et al. 10 The peri-and interfollicular FOXP3 + cells, 11 which are reportedly more numerous than those in the follicular compartment, 10 were not, therefore, included in our assessment. Nevertheless, the proportional decrease of FOXP3 + cells in FL and transformed DLBCL evolving from FL observed by us was 2.7-fold (from 94/mm 2 to 33/mm 2 ), which was similar to the 4.4-fold decrease observed by Carreras et al. (from 9.6 to 2.2%). Furthermore, the proportional differences in the amount of FOXP3 + cells in neoplastic follicles of FL and in normal GC from tonsils and lymph nodes were similar in the two studies. Our results cannot be compared to those of other publications on FL and DLBCL since the authors used a hot-spot quantification technique and did not detail their morphometric and case distribution data. 11, 23, 26 In cHL, some differences from the study by Alvaro et al. could also be related to the hot-spot technique.
9 Again, the relative proportion of cHL cases with FOXP3 + cell counts over the mean±10%, as used by Alvaro et al., 9 was similar to that in our study (20. 4% and 19.2%, respectively) .
Our study is the first to apply ROC curves for determination of cut-off levels. 37 Linking the results for the prognostic importance of FOXP3 + cell quantity in the various lymphoma subtypes to overall, disease-specific and failure-free survival, allowed the identification of distinct entity-specific cut-off values for FOXP3 + cell density for these clinical end-points. Analyzing the prognostic value of FOXP3 + cell quantity in a differentiated manner, we suggest a positive prognostic influence of an increased amount of these cells not only in FL and cHL, but also, by factoring the probable tumor cell origin in DLBCL, in GC-like DLBCL defined by Hans' algorithm, 36 which would have been masked when 
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analyzing all DLBCL cases collectively. 26 Taken together, our findings and previous observations, [9] [10] [11] [19] [20] [21] [22] point towards the possibility of retained direct or indirect cellular communications between Treg and B-cell lymphoma cells in GC-associated neoplasms. Since we were not able to define any correlation between FOXP3 + cell numbers and lymphoma cell cycle deregulation, surface protein expression or EpsteinBarr virus, particularly in cHL, we suggest that the ability of FOXP3 + Treg to directly suppress and even kill B cells, 21, 22 to suppress TFH and TFH-mediated B-cell functions such as survival, 19, 21 and to allow the accumulation of large numbers of TIA-1 + cells, 9,26 could be important in GC-derived lymphomas. Interestingly, the observed trend towards better overall survival in AILT with increased FOXP3 + cell numbers also points to possible retained cellular communication loops between Treg and GC TFH; the neoplastic cells of AILT being regarded as molecularly linked to TFH. 41 Contrary to GC-like DLBCL, but similarly to epithelial malignancies, in non-GC DLBCL and Hans'-unclassifiable DLBCL (data not shown), increased FOXP3 + cell numbers correlated with an adverse clinical outcome (disease-specific and failure-free survival rates) despite the fact that the absolute FOXP3 + cell numbers were similar in GC-like and non-GC DLBCL. The reason for this phenomenon is unclear, but assuming that non-GC DLBCL are derived from activated B-cells from later developmental stages, the recently observed dysfunctional Treg in another late-developmental stage B-cell neoplasia, multiple myeloma, is intriguing. 42 In such post-GC derived B-cell neoplasms, there might be additional cell communication loops leading to functional down-regulation of Treg. Indeed, the cytokines interleukin-6 and tumor necrosis factor-α are differently distributed among GC and non-GC DLBCL with particularly high levels in non-GC DLBCL.
43 Both interleukin-6 44,45 and tumor necrosis factor-α 46 can inhibit the function of Treg, suggesting that an increased number of Treg, more frequently observed by us in non-GC DLBCL with adverse clinical outcomes, may not reflect their functional activity.
In summary, our standardized TMA-based morphometric approach and ROC-based analysis for determining cutoff levels revealed profound quantitative differences in FOXP3 + cell distribution among different lymphoma entities, provided further evidence that FOXP3 + cells probably represent important lymphoma/host microenvironment modulators in distinct lymphoproliferative diseases, and demonstrated that increased FOXP3 + cell numbers can positively influence survival in GC-derived neoplasms such as FL, GC-like DLBCL and cHL.
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